Leukapheresis Industry Development and Demand Forecast to 2030

The leukapheresis market was sized at USD 71.4 million in 2022, which will power at a rate of 8.4% in the years to come, to touch USD 136.3 million by 2030.

The market is bifurcated into devices and disposables, depending on product, of which disposables held the dominating share in 2022, a situation that will likely remain unchanged.

The growing requirement for leukapheresis disposables because of the increasing leukemia occurrence is the key driver for the industry growth. Furthermore, the correct use of a number of disposables has the advantage of lowering the danger of infections throughout blood transfusions.

Research application had the larger revenue share, about 80%, in 2022, and it will maintain its dominance in the years to come. This is generally as a result of the rising use of leukapheresis products for the creation of cell-based immunotherapies, increasing requirement for leukopaks in scientific research, and mounting acceptance of leukapheresis-derived primary cells in pharma R&D.

The therapeutic application category will grow well. This is because of the robust global network of corporations offering leukapheresis equipment and disposables for therapy.

Furthermore, hospitals are quickly obtaining leukapheresis equipment for treating patients for numerous blood-borne disorders.

Leukapheresis is a process which is used to treat CLL and other types of blood cancer. Hence, the increase in the count of leukemia patients as a result of the deskbound lifestyles, smoking, and experience to radiation and specific substances is powering the market growth.

North America leukapheresis market had the largest share, of about 50%, in 2022, and it will grow at a healthy rate, according to P&S Intelligence. This will be as a result of the considerable R&D activities in the pharma and biotech sectors.

This also has a throttlehold because of the incidence of a large count of industry stalwarts and healthcare providers, the increased number of ongoing CAR T-cell therapy clinical trials, along with the elevated danger of pandemics and infectious diseases.

Moreover, the region's rapid acceptance of novel technologies and the increasing occurrence of chronic illnesses support the development of the regional sector.

APAC will grow the fastest in the years to come, mainly because of the improving healthcare infra, growing occurrence of leukemia, increasing per capita income, and growing elderly population.

Moreover, the industry is developing because of the government programs for supporting healthy lifestyles and raise consciousness and the tech improvements in hematology.

Furthermore, the development in the cancer hospitals network and blood donation and processing centers contributes to the industrial growth.

It is because of the increasing number of initiatives of the government for raising cancer awareness, the demand for leukapheresis will increase considerably in the years to come.

Market Size Breakdown by Segment

Based on Offering

• Devices

Centrifugal devices

Apheresis devices

Columns and cell separators

Leukoreduction filters

• Disposables

Based on Application

• Therapeutic
• Research

Based on End user

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Hospitals and Transfusion Centers
• Blood Component Providers and Blood Centers

Geographical Analysis

• North America

U.S.

Canada

• Europe

Germany

U.K.

France

Italy

Spain

• Asia-Pacific

Japan

China

India

South Korea

Australia

• Latin America

Brazil

Mexico

• Middle East and Africa

Saudi Arabia

South Africa

U.A.E.